Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data

NCT04647110 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04647110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
December 14, 2020
Completion date
March 15, 2021
Enrollment
549 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive nsclc